Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;103:1270-1279
Published online before print October 23, 2008, doi: 10.1161/CIRCRESAHA.108.182832
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
103/11/1270    most recent
CIRCRESAHA.108.182832v2
CIRCRESAHA.108.182832v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fan, G.-C.
Right arrow Articles by Kranias, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fan, G.-C.
Right arrow Articles by Kranias, E. G.
Related Collections
Right arrow Other myocardial biology
Right arrow Cardiovascular Pharmacology
Right arrow Apoptosis
(Circulation Research. 2008;103:1270.)
© 2008 American Heart Association, Inc.


Molecular Medicine

Heat Shock Protein 20 Interacting With Phosphorylated Akt Reduces Doxorubicin-Triggered Oxidative Stress and Cardiotoxicity

Guo-Chang Fan, Xiaoyang Zhou, Xiaohong Wang, Guojie Song, Jiang Qian, Persoulla Nicolaou, Guoli Chen, Xiaoping Ren, Evangelia G. Kranias

From the Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Ohio.

Correspondence to Guo-Chang Fan, PhD, Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575. E-mail fangg{at}ucmail.uc.edu

Doxorubicin (DOX) is a widely used antitumor drug, but its application is limited because of its cardiotoxic side effects. Heat shock protein (Hsp)20 has been recently shown to protect cardiomyocytes against apoptosis, induced by ischemia/reperfusion injury or by prolonged β-agonist stimulation. However, it is not clear whether Hsp20 would exert similar protective effects against DOX-induced cardiac injury. Actually, DOX treatment was associated with downregulation of Hsp20 in the heart. To elucidate the role of Hsp20 in DOX-triggered cardiac toxicity, Hsp20 was first overexpressed ex vivo by adenovirus-mediated gene delivery. Increased Hsp20 levels conferred higher resistance to DOX-induced cell death, compared to green fluorescent protein control. Furthermore, cardiac-specific overexpression of Hsp20 in vivo significantly ameliorated acute DOX-triggered cardiomyocyte apoptosis and animal mortality. Hsp20 transgenic mice also showed improved cardiac function and prolonged survival after chronic administration of DOX. The mechanisms underlying these beneficial effects were associated with preserved Akt phosphorylation/activity and attenuation of DOX-induced oxidative stress. Coimmunoprecipitation studies revealed an interaction between Hsp20 and phosphorylated Akt. Accordingly, BAD phosphorylation was preserved, and cleaved caspase-3 was decreased in DOX-treated Hsp20 transgenic hearts, consistent with the antiapoptotic effects of Hsp20. Parallel ex vivo experiments showed that either infection with a dominant-negative Akt adenovirus or preincubation of cardiomyocytes with the phosphatidylinositol 3-kinase inhibitors significantly attenuated the protective effects of Hsp20. Taken together, our findings indicate that overexpression of Hsp20 inhibits DOX-triggered cardiac injury, and these beneficial effects appear to be dependent on Akt activation. Thus, Hsp20 may constitute a new therapeutic target in ameliorating the cardiotoxic effects of DOX treatment in cancer patients.


Key Words: apoptosis • cardiomyopathy • doxorubicin • heat-shock protein • Akt




This article has been cited by other articles:


Home page
CirculationHome page
X.-P. Ren, J. Wu, X. Wang, M. A. Sartor, J. Qian, K. Jones, P. Nicolaou, T. J. Pritchard, and G.-C. Fan
MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat-Shock Protein 20
Circulation, May 5, 2009; 119(17): 2357 - 2366.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Miyamoto, M. Rubio, and M. A. Sussman
Nuclear and mitochondrial signalling Akts in cardiomyocytes
Cardiovasc Res, May 1, 2009; 82(2): 272 - 285.
[Abstract] [Full Text] [PDF]